Alex J. Buckmelter
Forma Therapeutics (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Protein Kinase Regulation and GTPase Signaling, HER2/EGFR in Cancer Research, Computational Drug Discovery Methods, Ubiquitin and proteasome pathways
Most-Cited Works
- → Pyrazolopyridine Inhibitors of B-RafV600E. Part 1: The Development of Selective, Orally Bioavailable, and Efficacious Inhibitors(2011)66 cited
- → Pyrazolopyridine inhibitors of B-RafV600E. Part 2: Structure–activity relationships(2011)56 cited
- → Potent and Selective Aminopyrimidine-Based B-Raf Inhibitors with Favorable Physicochemical and Pharmacokinetic Properties(2012)47 cited
- → Non-oxime inhibitors of B-RafV600E kinase(2010)28 cited
- → The Discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors(2010)26 cited
- → Imidazo[4,5-b]pyridine inhibitors of B-Raf kinase(2013)26 cited
- → Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-RafV600E kinase with favorable physicochemical and pharmacokinetic properties(2011)24 cited
- → The discovery of potent and selective pyridopyrimidin-7-one based inhibitors of B-RafV600E kinase(2012)17 cited
- ARRY-334543, A potent, orally active small molecule inhibitor of EGFR and ErbB-2(2005)
- → A novel USP30 inhibitor recapitulates genetic loss of USP30 and sets the trigger for PINK1-PARKIN amplification of mitochondrial ubiquitylation(2020)7 cited